Immunology and Immunotoxicology Endpoints in Early Drug Development

Date
Monday, November 16, 2020Mon, Nov 16, 2020
Duration
60 min
Ready On-Demand
Free — start watching in secondsFree

About this webinar

Immune system safety assessment has emerged as a significant and indispensable area of the drug preclinical development industry, especially for biologics. To help drug development sponsors better understand this rapidly growing field, this webinar provides a comprehensive overview of immunotoxicity assessment and its pivotal role in drug safety.

Join this webinar to gain insights into predicting potential immunotoxicity, understanding regulatory guidelines and comparing common investigative approaches. The speakers will cover core assays, which remain critical for compounds that impact the immune system, as well as discuss recent trends with translational assays such as cytokine release and receptor occupancy along with potential areas for advanced development.

Who should attend

  • Chief Medical Officer
  • Chief Executive officer
  • Clinical Operations
  • Clinical Development Manager/ Director
  • Clinical Director/ Senior Clinical Director
  • Commercial and Sales
  • Medical Affairs
  • Medical Director/ Senior Medical Director
  • Operational Director/ Senior Operational Director
  • Physicians
  • Project Management
  • Procurement Manager
  • Regulatory Specialist
  • Research Director/ Research and Development Director
  • Scientist/ Senior Scientist
  • Senior Medical Science Liaison

What you will learn

  • Understand the significance of conducting an immunotoxicology study during the drug safety assessment
  • Gain insights on general regulatory guidelines, principles, working scopes and investigative approaches of immunotoxicity studies
  • Learn how immunotoxicity findings are evaluated
  • Hear about emerging areas to address current challenges in immunotoxicology

Featured Speakers

Aric Frantz, DVM, PhD, I&I Senior Science Lead and Manager, Covance

Aric Frantz, DVM, PhD

I&I Senior Science Lead and Manager · Covance

Dr. Frantz is the North American Scientific Lead, senior manager for, and a founding member of, the Covance Immunology and Immunotoxicology department. He earned a PhD focused on comparative cancer immunology as part of a dual degree program, including a doctorate in veterinary medicine (DVM) from the University of Minnesota.

Amanda Lucchini, PhD, I&I SD/CS/PI and Manager, Covance

Amanda Lucchini, PhD

I&I SD/CS/PI and Manager · Covance

Dr. Lucchini joined Covance immunology and immunotoxicology team in 2018. Currently, Dr. Lucchini acts as a Study Director and Contributing Scientist for I&I, particularly focusing on method development and innovation. She is also the manager for the science/subject matter expert team at the Madison site. Dr Lucchini received her PhD from the University of Rochester focused on immunotoxicology and resolution of pulmonary inflammation.

Partner for this event

Covance

Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.

 Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.

Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.

Explore more webinars

Pick a topic to browse every free webinar in the Xtalks library on that subject.

Related keywords

Jump to every webinar tagged with a keyword from this one.

Not what you're looking for? Browse all webinars →

On-demand webinar